Branded generics occupy a middle ground between expensive branded drugs and bare-bones unbranded generics. These products use off-patent active ingredients […]
Off-Patent Drugs, On Profit: How Branded Generics Earn 20%+ Margins Read Post »
The pharmaceutical industry has long been viewed through a binary lens. On one side, the high-stakes, high-margin world of patented
The Trust Proxy: How To Charge 100% More For The Same Pill Read Post »
An investigative analysis of the business architecture behind pharma’s most durable profit model When Pfizer’s patent on atorvastatin expired in
The Margin Machine: How Branded Generics Print 20%+ Returns on Drugs Anyone Can Make Read Post »
The maturation of algorithmic discovery The pharmaceutical industry reached an inflection point in 2025 as artificial intelligence transitioned from a
How to fix the $2.6 billion drug discovery problem Read Post »
The pharmaceutical industry is struggling with its own productivity. The cost of bringing a single new chemical entity to market
The Asset Rescue Playbook: Turning Off-Patent Data into High-Margin Monopolies Read Post »
1. The Economics of Managed Exclusivity The pharmaceutical industry operates on a unique economic premise: huge upfront investment in research
Litigate, Settle, Repeat: The Strategic Architecture of Sequential Patent Suits Read Post »
Executive Summary The pharmaceutical sector currently faces a distinct legal friction where federal health policy conflicts with intellectual property statutes.
Executive Summary The biopharmaceutical and life sciences sectors face a central, defining strategic tension: the optimal allocation of capital between
The Capital Allocation Pain Point: Balancing R&D Burn with Defensible IP to Maximize ROI Read Post »
In the high-stakes world of pharmaceuticals and biotechnology, intellectual property (IP) is no longer a simple legal instrument; it is
Global Patent Thickets: The Cross-Border Pain Point Read Post »
Sign in or create a free account to read this DrugPatentWatch article
